Clinical Trial Update: Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial [Phase 2]

View source ↗

Summary

A Phase II randomized trial is evaluating disitamab vedotin plus the SOX chemotherapy regimen versus SOX alone as adjuvant therapy in HER2-expressing stage III …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: GC/GEJC | Phase 2 | Status: RECRUITING